MARKET

SMMT

SMMT

SUMMIT THERAP
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.290
0.000
0.00%
Closed 17:02 07/06 EDT
OPEN
3.280
PREV CLOSE
3.290
HIGH
3.295
LOW
3.225
VOLUME
30.05K
TURNOVER
--
52 WEEK HIGH
5.49
52 WEEK LOW
1.180
MARKET CAP
221.19M
P/E (TTM)
-3.3561
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SMMT stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.

EPS

SMMT News

More
Summit Therapeutics Announces Michael Donaldson CFO
Benzinga · 06/08 11:08
Summit Appoints Michael Donaldson as Chief Financial Officer
Summit Therapeutics plc (SMMT) today announces that Mr. Michael Donaldson has been appointed as Chief Financial Officer, effective immediately. Mr. Donaldson brings to Summit over 20 years of finance experience, including the last nine years working in corpor
GlobeNewswire · 06/08 11:00
Is Summit Therapeutics PLC (SMMT) A Good Stock To Buy?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite inve
Insider Monkey · 06/05 01:47
Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know
Zacks · 06/02 22:45
Summit Therapeutics Q1 Sales $315.00K Down From $324.00K YoY
Summit Therapeutics (NASDAQ:SMMT) reported $315.00 thousand in sales this quarter. This is a 2.78 percent decrease over sales of $324.00 thousand the same period last year.
Benzinga · 06/02 20:02
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months.
GlobeNewswire · 06/02 20:01
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?
Is (SMMT) Outperforming Other Medical Stocks This Year?
Zacks · 06/01 15:30
Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know
Summit Therapeutics PLC (SMMT) closed at $4.20 in the latest trading session, marking a +1.94% move from the prior day.
Zacks · 05/27 21:45

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.72%

Hot Stocks

Symbol
Price
%Change

About SMMT

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the infectious disease Clostridium difficile infection (CDI). Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid.
More

Webull offers kinds of Summit Therapeutics PLC stock information, including NASDAQ:SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.